Premium
Antiparkinsonian activity of single oral dose of PHNO
Author(s) -
Grandas F.,
Quinn N.,
Critchley P.,
Rohan A.,
Marsden C. D.,
Stahl S. M.
Publication year - 1987
Publication title -
movement disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.352
H-Index - 198
eISSN - 1531-8257
pISSN - 0885-3185
DOI - 10.1002/mds.870020106
Subject(s) - agonist , medicine , pharmacology , parkinson's disease , adverse effect , anesthesia , disease , receptor
PHNO, a new D‐2 agonist, was investigated in five patients with Parkinson's disease. In an acute, open, oral, dose‐ranging study comparing benefit from single doses, 4 mg of PHNO was found to be equivalent to one tablet of Sinemet 25/250 mg. Adverse reactions were those anticipated for a dopaminomimetic agent. Because of its novel structure and apparent transcutaneous penetration, further studies on PHNO are desirable.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom